Samalin Investment Counsel, LLC Halozyme Therapeutics, Inc. Transaction History
Samalin Investment Counsel, LLC
- $234 Million
- Q1 2025
A detailed history of Samalin Investment Counsel, LLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Samalin Investment Counsel, LLC holds 10,729 shares of HALO stock, worth $578,614. This represents 0.29% of its overall portfolio holdings.
Number of Shares
10,729
Previous 10,607
1.15%
Holding current value
$578,614
Previous $507,000
34.91%
% of portfolio
0.29%
Previous 0.23%
Shares
8 transactions
Others Institutions Holding HALO
# of Institutions
595Shares Held
124MCall Options Held
320KPut Options Held
113K-
Black Rock Inc. New York, NY17.6MShares$950 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.8MShares$692 Million0.02% of portfolio
-
State Street Corp Boston, MA6.05MShares$326 Million0.02% of portfolio
-
Invesco Ltd. Atlanta, GA3.89MShares$210 Million0.05% of portfolio
-
Snyder Capital Management L P San Francisco, CA3.67MShares$198 Million5.31% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $7.51B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...